Latest news with #ALPINE
&w=3840&q=100)
Business Standard
10-06-2025
- Business
- Business Standard
Glenmark Pharma rises 2% as company to launch blood cancer treatment drug
Glenmark Pharma share price rose 1.7 per cent in trade on Tuesday, June 10, 2025, logging an intraday high at ₹1,626.6 per share on BSE. At 10:30 AM, Glenmark Pharma shares were trading 1.56 per cent higher at ₹1,623.35 per share on the BSE. In comparison, the BSE Sensex was up 0.05 per cent at 82,482.52. The company's market capitalisation stood at ₹45,811.07 crore. Its 52-week high was at ₹1,830.05 per share and 52-week low was at ₹1,176 per share. In the past one year, Glenmark shares have gained 33 per cent as compared to Sensex's rise of around 8 per cent. What is boosting rally in Glenmark Pharma shares? The stock gained after the company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India. Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies. According to the filing, Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments. The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs. In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. About BeOne Medicines BeOne Medicines, formerly known as BeiGene, is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.
&w=3840&q=100)
Business Standard
09-06-2025
- Business
- Business Standard
Glenmark set to launch blood cancer treatment drug Brukinsa in India
Glenmark Pharmaceuticals Ltd, a global pharmaceutical company, is set to introduce zanubrutinib in India under the brand name Brukinsa, following approval from the Drugs Controller General of India (DCGI). Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies. Approved in over 70 countries Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments. The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs. In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications. "We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," said Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals. 'This launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety. It underscores Glenmark's ongoing commitment to providing effective and advanced treatments for patients with haematological malignancies," he added. Global partnership expands to India Adam Roach, Senior Vice President and Head of the Japan and Asia Pacific region at BeiGene, commented: 'The introduction of Brukinsa in India marks an important step in our ongoing mission to expand patient access to innovative oncology treatments across the Asia Pacific region.' 'We are proud to support Glenmark in bringing this therapy to patients in India, furthering our shared commitment to improve healthcare outcomes globally,' he said.
Business Standard
09-06-2025
- Health
- Business Standard
Glenmark receives DCGI approval to launch oncology drug BRUKINSA in India
Glenmark Pharmaceuticals has announced the upcoming launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). Zanubrutinib will be marketed in India under the brand name BRUKINSA, an innovative therapy developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. BRUKINSA is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstr macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). Globally, BRUKINSA is approved in more than 70 countries, supported by compelling clinical evidence from pivotal trials including ALPINE, ASPEN, and SEQUOIA. This extensive clinical program underscores BRUKINSA's proven efficacy, strong safety profile, and broad therapeutic value. The introduction of BRUKINSA brings an innovative treatment option at a time when India continues to face a significant burden from serious and difficult-to-treat haematological malignancies. According to various sources, someone in India is diagnosed with blood cancer every five minutes, and an estimated 70,000 people die from the disease each year. BRUKINSA addresses a critical unmet need with its differentiated pharmacological profile, demonstrating high response rates and durable disease control across multiple B-cell malignancies as shown in pivotal clinical trials. BRUKINSA's flexible dosing regimen (once or twice daily) supports personalized care.1 In the head-to-head ALPINE study in relapsed/refractory chronic lymphocytic leukemia, BRUKINSA demonstrated a lower rate of serious cardiac events (1.9% vs. 7.7%) and fewer treatment discontinuations due to cardiac issues (0.3% vs. 4.3%) compared with ibrutinib.
Business Upturn
09-06-2025
- Business
- Business Upturn
Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval
Glenmark Pharmaceuticals has announced the launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). The drug will be marketed under the brand name BRUKINSA®, developed by BeiGene (now BeOne Medicines), a global oncology company. This marks the introduction of the first Bruton's tyrosine kinase (BTK) inhibitor in India approved for the treatment of five B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). BRUKINSA is approved in over 70 countries, backed by data from clinical studies such as ALPINE, ASPEN, and SEQUOIA. These trials have demonstrated consistent clinical outcomes across various B-cell cancers. The availability of BRUKINSA in India comes at a time when blood cancers continue to impact a large number of individuals. Estimates suggest that someone is diagnosed with blood cancer every five minutes in India, with annual deaths from the disease numbering around 70,000. The treatment has shown high response rates and the ability to maintain disease control in patients with different types of B-cell malignancies. It also offers dosing flexibility, allowing for once or twice-daily administration. In the ALPINE study, BRUKINSA was compared with ibrutinib in relapsed or refractory CLL and showed a lower rate of serious cardiac events and fewer treatment discontinuations due to cardiac-related issues. With its recent regulatory approval, BRUKINSA will now be available to patients in India who are affected by challenging hematological cancers. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Hindustan Times
23-04-2025
- Politics
- Hindustan Times
India and Pakistan could come to blows over Kashmir
THE ALPINE meadows and pine forests of Pahalgam have long been a lure for visitors to the Indian region of Jammu & Kashmir. They called it 'mini-Switzerland' and came in greater numbers lately as India's government hailed a downturn in militant violence in the region. Yet on April 22nd, at least 20 people were killed and many more injured after unidentified gunmen opened fire on tourists in Pahalgam. It appears to have been the deadliest militant attack since 2019 in the Himalayan region, which is claimed in full but ruled in part by both India and Pakistan. While Indian police blamed militants fighting Indian rule, a group calling itself the 'Resistance Front' claimed responsibility on social media, citing an influx of 85,000 settlers. But former Indian military and intelligence officials accused Pakistan's armed forces of masterminding the assault and called for a strong and swift response. After the 2019 attack, which killed 40 Indian policemen, India carried out an air strike on Pakistan 12 days later. Pakistan's air force struck back the next day and as Indian jets responded, one crashed in Pakistani territory, although the pilot survived and was quickly returned to India. The Pahalgam attack, which coincided with a visit to India by America's vice-president, J.D. Vance, threatens to trigger another military confrontation between India and Pakistan, which both have nuclear weapons and have fought two wars, plus one more limited conflict, over Kashmir since their independence in 1947. Mr Vance, who is visiting cultural sites in northern India (several hundred miles away), offered his condolences to the victims of what he called a 'devastating terrorist attack'. President Donald Trump said America 'stands strong with India against terrorism'. India's prime minister, Narendra Modi, who is visiting Saudi Arabia, vowed to bring the perpetrators to justice. 'They will not be spared!' he posted on X. 'Our resolve to fight terrorism is unshakable.' Amit Shah, the Indian home minister, rushed to Kashmir to hold a security meeting. 'This attack on our visitors is an abomination,' said Omar Abdullah, the region's top elected official. It was 'much larger than anything we've seen directed at civilians in recent years.' Indian media reports said two of the dead were foreigners of Indian origin but did not give their nationalities. The attack is a blow to the Indian government's claims to have stabilised Kashmir. Tens of thousands of people have been killed there since the start of an anti-Indian insurgency in 1989. But in recent years militant violence appeared to have subsided. India's government credited that to its decision to revoke Kashmir's semi-autonomous status in 2019, splitting what had been an Indian state into two federally administered territories: Jammu & Kashmir, and Ladakh. That allowed tens of thousands of outsiders to get jobs and buy land in the region. Tourist numbers increased. But it also led to a deterioration of ties with Pakistan. In a speech this month Pakistan's army chief, General Asim Munir, described Kashmir as 'our jugular vein'. He continued: 'We will not forget it. And we will not leave our Kashmiri brethren in their heroic struggle.' Former Indian military and security officials suggested that the perpetrators had wanted to draw international attention to Kashmir by planning the attack to coincide with Mr Vance's visit to India and Mr Modi's to Saudi Arabia. They also suggested that the attack was designed to undermine Kashmir's tourist industry, as it came a few weeks before a big Hindu pilgrimage. The last deadly incident in the region was in June 2024 when nine people died after a militant attack caused a bus carrying Hindu pilgrims to plunge into a gorge. India's government then launched a major operation to find the perpetrators and pledged to strengthen security. This time, expect public calls for much firmer action.
